Sionna's post-earnings short squeeze faded, with short interest rising to 23.7% of free float as the stock slipped 10% last week. Raymond James backed the biotech with a 'Strong Buy' and $45 target, citing its potential to rival Vertex in cystic fibrosis, while RBC set a cautious $22 target, warning existing treatments set a high bar.